CoChat

Direct Comparison of 2 Rule-Out Strategies for Acute Myocardial Infarction: 2-h Accelerated Diagnostic Protocol vs 2-h Algorithm

Wildi, Karin, Cullen, Louise, Twerenbold, Raphael, Greenslade, Jaimi H, Parsonage, William, Boeddinghaus, Jasper, Nestelberger, Thomas, Sabti, Zaid, Rubini-Giménez, Maria, Puelacher, Christian, Cupa, Janosch, Schumacher, Lukas, Badertscher, Patrick, Grimm, Karin, Kozhuharov, Nikola, Stelzig, Claudia, Freese, Michael, Rentsch, Katharina, Lohrmann, Jens, Kloos, Wanda, Buser, Andreas, Reichlin, Tobias, Pickering, John W, Than, Martin, Mueller, Christian · 2017 · Clinical Chemistry
Cited by 37

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

BACKGROUND: We compared 2 high-sensitivity cardiac troponin (hs-cTn)-based 2-h strategies in patients presenting with suspected acute myocardial infarction (AMI) to the emergency department (ED): the 2-h accelerated diagnostic protocol (2h-ADP) combining hs-cTn, electrocardiogram, and a risk score, and the 2-h algorithm exclusively based on hs-cTn concentrations and their absolute changes. METHODS: Analyses were performed in 2 independent diagnostic cohorts [European Advantageous Predictors of Acute Coronary Syndrome Evaluation (APACE) study, Australian–New Zealand 2-h Accelerated Diagnostic Protocol to Assess patients with chest Pain symptoms using contemporary Troponins as the only biomarker (ADAPT) study] employing hs-cTnT (Elecsys) and hs-cTnI (Architect). The final diagnosis was adjudicated by 2 independent cardiologists. RESULTS: AMI was the final diagnosis in 16.5% (95% CI, 14.6%–18.6%) of the 1372 patients in APACE, and 12.6% (95% CI, 10.7%–14.7%) of 1153 patients in ADAPT. The negative predictive value (NPV) and sensitivity for AMI were very high and comparable with both strategies using either hs-cTnT or hs-cTnI in both cohorts (all statistical comparisons nonsignificant). The percentage of patients triaged toward rule-out was significantly lower with the 2h-ADP (36%–43%) vs the 2-h algorithm (55%–68%) with both assays and in both cohorts (P < 0.001). The sensitivity of the 2h-ADP was higher for 30-day major adverse cardiovascular events. CONCLUSIONS: Both algorithms provided very high and comparable safety as quantified by the NPV and sensitivity for AMI and major adverse cardiac events (MACE) at 30 days in patients triaged toward rule-out, although sensitivity for MACE at 30 days was lower with both algorithms in cohort 2. Although the 2-h algorithm was more efficacious, not all patients ruled out for AMI by this algorithm were appropriate candidates for early discharge. The 2h-ADP seems superior in the selection of patients for early discharge from the ED. CLINICAL TRIAL REGISTRATION: APACE: http://clinicaltrials.gov/show/NCT00470587 ADAPT: Australia-New Zealand Clinical Trials Registry ACTRN12611001069943

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1373/clinchem.2016.268359

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 37

Metadata

Authors
Wildi, K., Cullen, L., Twerenbold, R., Greenslade, J. H., Parsonage, W., Boeddinghaus, J., Nestelberger, T., Sabti, Z., Rubini-Giménez, M., Puelacher, C., Cupa, J., Schumacher, L., Badertscher, P., Grimm, K., Kozhuharov, N., Stelzig, C., Freese, M., Rentsch, K., Lohrmann, J., Kloos, W., Buser, A., Reichlin, T., Pickering, J. W., Than, M., & Mueller, C.
Venue
Clinical Chemistry
Published
2017-07-01
Volume
63
Issue
7
Pages
1227-1236
ISSN
  • 0009-9147 (ISSN-L)
  • 1530-8561
OpenAlex
W2615507728
Cited by
37
References
3
FWCI
3.26
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.